Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.

In the most recent trading session, JPMorgan Chase & Co. (JPM) closed at $317.21, indicating a +1.35% shift from the previous trading day.

In the latest trading session, Applied Materials (AMAT) closed at $256.41, marking a +1.15% move from the previous day.

In the closing of the recent trading day, Coinbase Global, Inc. (COIN) stood at $245.12, denoting a +2.47% move from the preceding trading day.

The S&P 500 is on a roll, but another index fund has nearly doubled it during the AI era. The QQQ ETF offers exposure to the 100 largest Nasdaq stocks.

Oracle's ORCL relationship with OpenAI has become a never-ending source of market angst, as the tie-in reminds many of questionable vendor-financing practices from the late 1990s. Tied to Oracle's OpenAI exposure are questions about the company's financial health and its ability to fund its data center expansion plans.

cbdMD, Inc. (YCBD) Q4 2025 Earnings Call Transcript

Genco Shipping (GNK) received a $20.60/share cash buyout proposal from Diana Shipping (DSX), validating the bull thesis of asset undervaluation. DSX seeks GNK's strong balance sheet and cash flows to offset its own leverage, but the offer is near or below GNK's NAV and lacks a control premium. GNK's poison pill and robust financials empower the board to demand a higher bid or shop for alternative offers, with fair value estimated at $24–25/share.

Micron's blockbuster earnings report helped set off a rally in the AI market. Applied Digital announced on Thursday that it has secured new funding from a key financing partner.

UPS surged higher after a well-received earnings release in October, and has continued to climb higher throughout the holiday season. Now trading at around $100 per share, you may be wondering whether now is the time to buy.

CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.

It announced a new partnership with a defense company. That partner, C Speed, specializes in radar technology.

CNBC's “Fast Money” team shares their final trades of the day.

Rocket Lab has won an $816 million contract — its largest to date — with the U.S. Space Development Agency as the company continues to diversify beyond its “rocket company” label.

Well-known tech stocks were buoyed by improved sentiment in the sector as the trading week came to a close. This one is prominent thanks to its specialized AI products.

The S&P 500 had a rough start to the week but finished on solid footing, ultimately finishing up 0.1% from last Friday. Here is a snapshot of the index from the past week: The table below summarizes the number of record highs reached each year dating back to 2013.

SAN DIEGO , Dec. 19, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance[] the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.

Calgary, Alberta--(Newsfile Corp. - December 19, 2025) - Baytex Energy Corp. (TSX: BTE) (NYSE: BTE) ("Baytex" or the "Company") today announced that it has closed the sale of its U.S. Eagle Ford Assets for net proceeds of US$2.14 billion (approximately $2.96 billion in Canadian dollars) after closing adjustments. This strategic divestiture significantly strengthens Baytex's financial position and sharpens its focus on a high-return Canadian energy platform, positioning the Company for long-term value creation.

Citigroup resumed coverage with a buy rating but slashed its price target from $192 to $135 and added a high-risk designation. Micron's record earnings report helped ease broader concerns about an AI sector bubble.

IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today reported the grants in December totaling 392,158 restricted stock units (RSUs) of the Company's common stock to newly hired non-executive employees of the Company.